Newsbenzinga
Medicus Pharma Optimizes Portfolio Strategy With High-Value Focus
· Published
Article summary
Medicus Pharma narrows SkinJect development to Gorlin syndrome, targeting a $1.1 billion market and seeking key FDA orphan designations.
An excerpt from the original article.
Comments —
Loading comments…